By: Adam Feuerstein | 01/22/14 - 10:32 AM EST
Stifel analyst Stephen Willey issued a new bullish note on
(NLNK - Get Report) this morning. I'm here to help interpret what it all means.
The headline on Willey's note reads: Still Quite Comfortable with Valuation Here - Increasing Target Price to $53
Translation: Newlink has exceeded my previous $31-per-share price target and my director of research told me that I have "to do something about it."
Willey: We are now modeling approximately $1B of peak IDO pathway inhibitor sales.
Translation: Wow! I found some new money under Newlink's couch cushions.
Willey: While acknowledging the lack of an indication-specific registrational development plan admittedly limits our ability to accurately assess the true market opportunity here, we're more than comfortable with the preclinical data generated to date...
Translation: I have absolutely no idea how to accurately forecast peak sales for a product with a teeny amount of clinical data but $1 billion is a nice round number and reads well on the Bloomberg terminal.
Willey: We still view success at the first IMPRESS interim analysis as a low-probability event but believe the growing enthusiasm around the IDO story should mitigate any associated downside.
Translation: All my hedge fund clients think dendritic cancer vaccines suck and Newlink's algenpantucel-L is no exception, so yeah, the phase III study will probably fail but buy the stock anyway because IDOs are the new checkpoint inhibitors!
01/30/15 - 06:01 AM EST
01/29/15 - 07:44 AM EST
01/13/15 - 09:12 AM EST
01/12/15 - 07:07 AM EST
01/09/15 - 02:56 PM EST
01/30/15 - 09:31 AM EST
01/29/15 - 11:30 AM EST
01/28/15 - 08:57 AM EST
01/27/15 - 09:24 AM EST
01/26/15 - 09:15 AM EST
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.